

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

EQA round: TDM2/17 - Therapeutic Drugs

Dead line: 13.10.2017

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Traceability								
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
Set of samples 1															
(81) Digoxin					128										
Samples and groups		[nmol/L]													
Sample A1		2,14	0,28	13	128										
(1) FIA, FPIA, DELFIA		2,25	0,22	9,9	7	0									
(2) EIA (EMIT, CEDIA)		2,13	0,26	12	8	0									
(4) LIA, ILMA		2,08	0,32	16	72	0									
(6) Immunoturbidimetry		2,21	0,20	9,2	40	0									
Other					1	0									
Sample B1		2,54	0,31	12	128										
(1) FIA, FPIA, DELFIA		2,66	0,15	5,6	7	0									
(2) EIA (EMIT, CEDIA)		2,54	0,33	13	8	0									
(4) LIA, ILMA		2,48	0,36	14	72	0									
(6) Immunoturbidimetry		2,63	0,23	8,7	40	0									
Other					1	0									
(82) Theophylline					89										
Samples and groups		[µmol/L]													
Sample A1		109	7,8	7,2	89										
(1) FIA, FPIA, DELFIA		113	5,0	4,4	14	0									
(2) EIA (EMIT, CEDIA)		107	4,0	3,7	9	0									
(4) LIA, ILMA		109	9,4	8,6	37	0									
(6) Immunoturbidimetry		106	6,9	6,5	28	0									
Other					1	0									
Sample B1		66,1	4,9	7,5	89										
(1) FIA, FPIA, DELFIA		68,2	2,4	3,6	14	0									
(2) EIA (EMIT, CEDIA)		64,9	3,3	5,1	9	0									
(4) LIA, ILMA		67,4	7,1	10	37	0									
(6) Immunoturbidimetry		64,9	3,7	5,7	28	0									
Other					1	0									
(83) Primidone					9										
Samples and groups		[µmol/L]													
Sample A1		47,8	4,1	8,5	9	CVP	47,8	5,0	24%	36,3	59,3	9	9	100%	0
(3) HPLC, GC		45,4	2,7	6,0	5	0						5			
Other					4	0						4			
Sample B1		43,9	4,4	10	9	CVP	43,9	5,5	24%	33,3	54,5	9	9	100%	0
(3) HPLC, GC		40,2	4,4	11	5	0						5			

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

EQA round: TDM2/17 - Therapeutic Drugs

Dead line: 13.10.2017

Test	[unit]	Comparability						Traceability															
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(87) Ethosuximide					9							9	8	89%									0
Samples and groups	[µmol/L]																						
Sample A1		577	61	11	9		CVP	577	75	24%	438	716		9	9	100%							0
(3) HPLC, GC		548	38	6,9	6	0								6									
Other					3	0								3									
							1x 2, 2x 5																
Sample B1		192	18	9,4	9		CVP	192	22	24%	145	239		9	8	89%							0
(3) HPLC, GC		187	13	7,2	6	0								6									
Other					3	0								3									
							1x 2, 2x 5																
(88) Valproic acid					84									84	82	98%							0
Samples and groups	[µmol/L]																						
Sample A1		216	17	7,8	84		CVP	216	4,5	20%	172	260		84	82	98%							0
(1) FIA, FPIA, DELFIA		212	7,2	3,4	15	0								15									
(2) EIA (EMIT, CEDIA)		227	12	5,4	19	0								19									
(4) LIA, ILMA		210	17	8,2	36	0								36									
(6) Immunoturbidimetry		222	26	12	14	0								14									
Sample B1		536	34	6,3	84		CVP	536	9,0	20%	428	644		84	83	99%							0
(1) FIA, FPIA, DELFIA		534	15	2,8	15	0								15									
(2) EIA (EMIT, CEDIA)		560	41	7,4	19	0								19									
(4) LIA, ILMA		519	40	7,7	36	0								36									
(6) Immunoturbidimetry		552	32	5,7	14	0								14									
							4x 2																
Set of samples 2																							
(89) Amicacin					29									29	26	90%							0
Samples and groups	[µmol/L]																						
Sample A2		4,60	0,96	21	29		CVP	4,6	0,44	42%	2,66	6,54		29	27	93%							0
(1) FIA, FPIA, DELFIA		4,40	0,83	19	7	0								7									
(6) Immunoturbidimetry		4,50	0,92	20	18	0								18									
Other					4	0								4									
							4x 2																
Sample B2		24,9	1,5	6,2	29		CVP	24,9	0,70	20%	19,9	29,9		29	28	97%							0
(1) FIA, FPIA, DELFIA		24,7	1,0	4,2	7	0								7									
(6) Immunoturbidimetry		25,1	1,5	5,9	18	0								18									
Other					4	0								4									
							4x 2																
(90) Gentamicin					55									55	54	98%							0
Samples and groups	[µmol/L]																						
Sample A2		13,0	1,7	13	55		CVP	13	0,55	31%	8,97	17,1		55	54	98%							0
(1) FIA, FPIA, DELFIA		12,7	0,64	5,0	10	0								10									
(4) LIA, ILMA		13,4	1,3	10	23	0								23									
(6) Immunoturbidimetry		12,8	2,4	19	18	0								18									
Other					4	0								4									
							4x 2																
Sample B2		9,61	1,1	12	55		CVP	9,61	0,38	31%	6,63	12,6		55	55	100%							0
(1) FIA, FPIA, DELFIA		9,36	0,48	5,1	10	0								10									
(4) LIA, ILMA		9,89	0,88	8,9	23	0								23									
(6) Immunoturbidimetry		9,29	1,6	17	18	0								18									

